Rajan Sharma
Stock Analyst at Goldman Sachs
(2.64)
# 2,762
Out of 4,405 analysts
187
Total ratings
51.9%
Success rate
1.6%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Hold | 1,870p | $1,962.50 | -4.71% | 29 | Jun 9, 2026 | |
| IMTX Immatics | Rated: Buy | $11 → $12 | $9.06 | +34.66% | 4 | May 12, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €827.00 → €850.00 | $764.60 | +11.17% | 15 | May 8, 2026 | |
| LON: 0MGB Genmab A/S | Reiterated: Buy | kr 2,200 → kr 2,300 | $1,603.21 | +43.46% | 5 | May 8, 2026 | |
| IMCR Immunocore Holdings | Maintained: Buy | $72 → $73 | $28.62 | +155.07% | 12 | May 7, 2026 | |
| GMAB Genmab | Upgraded: Buy | $26 → $31 | $25.24 | +20.84% | 4 | Apr 22, 2026 | |
| VALN Valneva SE | Downgraded: Sell | $7.5 → $4.9 | $5.29 | -7.37% | 5 | Apr 22, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,600p | $13,578.00 | +22.26% | 36 | Apr 21, 2026 | |
| DBVT DBV Technologies | Maintained: Sell | $7.25 → $5.81 | $16.54 | -64.87% | 3 | Apr 9, 2026 | |
| EPA: DBV DBV Technologies S.A. | Rated: Sell | €1.30 → €1.01 | $2.82 | -64.24% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | €25.00 → €18.00 | $22.55 | -20.18% | 8 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €304.00 → €299.00 | $264.40 | +13.09% | 7 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $813 → $910 | $898.94 | +1.23% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.97 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.55 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7.6 → $5.7 | $1.56 | +265.38% | 5 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $51.58 | -12.76% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €2.85 → €3.30 | $2.21 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $70.73 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $156 → $171 | $44.70 | n/a | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 2.00 | $4.53 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $52.86 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $121.54 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $29.73 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €90.00 → €100.00 | $157.10 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €44.00 | $50.90 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $10.68 | n/a | 2 | May 4, 2022 |
GSK plc
Jun 9, 2026
Maintained: Hold
Price Target: 1,870p
Current: $1,962.50
Upside: -4.71%
Immatics
May 12, 2026
Rated: Buy
Price Target: $11 → $12
Current: $9.06
Upside: +34.66%
argenx SE
May 8, 2026
Maintained: Buy
Price Target: €827.00 → €850.00
Current: $764.60
Upside: +11.17%
Genmab A/S
May 8, 2026
Reiterated: Buy
Price Target: kr 2,200 → kr 2,300
Current: $1,603.21
Upside: +43.46%
Immunocore Holdings
May 7, 2026
Maintained: Buy
Price Target: $72 → $73
Current: $28.62
Upside: +155.07%
Genmab
Apr 22, 2026
Upgraded: Buy
Price Target: $26 → $31
Current: $25.24
Upside: +20.84%
Valneva SE
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $5.29
Upside: -7.37%
AstraZeneca PLC
Apr 21, 2026
Maintained: Buy
Price Target: 16,600p
Current: $13,578.00
Upside: +22.26%
DBV Technologies
Apr 9, 2026
Maintained: Sell
Price Target: $7.25 → $5.81
Current: $16.54
Upside: -64.87%
DBV Technologies S.A.
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: $2.82
Upside: -64.24%
Apr 9, 2026
Rated: Hold
Price Target: €25.00 → €18.00
Current: $22.55
Upside: -20.18%
Mar 2, 2026
Maintained: Buy
Price Target: €304.00 → €299.00
Current: $264.40
Upside: +13.09%
Feb 26, 2026
Maintained: Buy
Price Target: $813 → $910
Current: $898.94
Upside: +1.23%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.97
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.55
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: $7.6 → $5.7
Current: $1.56
Upside: +265.38%
Jul 30, 2025
Maintained: Buy
Price Target: $35 → $45
Current: $51.58
Upside: -12.76%
Mar 21, 2025
Maintained: Hold
Price Target: €2.85 → €3.30
Current: $2.21
Upside: n/a
Oct 3, 2024
Maintained: Hold
Price Target: n/a
Current: $70.73
Upside: n/a
Aug 16, 2024
Maintained: Buy
Price Target: $156 → $171
Current: $44.70
Upside: n/a
Jul 30, 2024
Maintained: Hold
Price Target: CHF 2.00
Current: $4.53
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $52.86
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $121.54
Upside: n/a
Dec 20, 2023
Maintained: Buy
Price Target: n/a
Current: $29.73
Upside: n/a
Feb 13, 2023
Maintained: Hold
Price Target: €90.00 → €100.00
Current: $157.10
Upside: n/a
May 16, 2022
Maintained: Hold
Price Target: €44.00
Current: $50.90
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $10.68
Upside: n/a